undamentalytics Newsletter
Sign in

Compass Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Compass Therapeutics, Inc. had return on equity of -41.3%, debt equal to 0.0% of equity and a current ratio of 15.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Operating margin—<−999%—
Net margin—<−999%—
Free-cash-flow margin—<−999%—
Return on equity−28.6%−36.1%−41.3%
Return on assets−27.1%−33.2%−36.9%
Asset turnover—0.01—
Current ratio19.7314.9615.02
Debt to equity0.0%0.0%0.0%
R&D as % of revenue—>999%—
Capital spending as % of revenue—5.2%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Compass Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Compass Therapeutics, Inc.